Monday, 18 Feb 2019

You are here

FDA Panel Votes to Favor High Dose Xeljanz in Ulcerative Colitis

Yesterday a FDA advisory panel voted 15-0 in favor of approving Xeljanz (tofacitinib) 10 mg bid for patients with moderate to severe ulcerative colitis.

The US Food and Drug Administration’s (FDA) convened the Gastrointestinal Drugs Advisory Committee Meeting (GIDAC) to assess Pfizers supplemental new drug application for tofacitinib in adult patients with moderately to severely active ulcerative colitis (UC).

This panel is advisory to the FDA and no decision has yet been made on drug approval; although the FDA usually follows advisory panel recommendations.  

Tofacitinib is currently approved for use in rheumatoid arthritis and psoriatic arthritis at a dose of 5 mg bid (or 11 mg once daily).  This new recommendation for approval of the 10 mg bid dose would be the first approval of "high dose" Xeljanz.  Although higher doses were studied and petitioned for by Pfizer, the FDA has only approved the lower dose noting no substantial efficacy advantage while questioning the safety of the higher dose.

If approved, tofacitinib will be the first JAK inhibitor and the first oral therapy for patients with active ulcerative colitis.  It would also be the 2nd approval for tofacitinib within a 6 month period.

The company proposed an initial 8 week regimen of tofacitinib 10 mg BID for induction to be followed by tofacitinib 5 mg BID for maintenance.  But the panel voted 8-7 against a post-marketing efficacy study comparing a tofacitinib 10 mg BID continuous dosing regimen versus a regimen of tofacitinib 10 mg BID induction and 5 mg BID maintenance.

A decision on this application is expected by June 2018.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Stopping Biologics Before Joint Surgery: Is Earlier Better?

Withholding intravenous abatacept (Orencia) for longer than a month before hip or knee arthroplasty among patients with rheumatoid arthritis (RA) did not lower the risk for postoperative infection, a retrospective claims-based analysis found.

Biologic High Out of Pocket Costs for Medicare Patients

Specialty tier drugs, including biologics, accounts for nearly half of all medication spending by Medicare Part D patients. High out-of-pocket costs for these patients is a major concern. 

RheumNow Podcast – TNFs and the Inflammasome (1.25.19)

Dr Jack Cush reviews the news from the past week at RheumNow.com.

Smoking Doesn't Influence Rituximab Responses in Rheumatoid Arthritis

Alcohol, smoking and obesity have all been shown to influence the risk and activity of rheumatoid arthritis (RA) and may also influence response to therapy. This study assesssed whether smoking would influence response to rituximab (RTX) in RA. 

Anakinra for Acute Crystal-Induced Arthritis

A retrospective analysis of hospitalized patients who also had a gout and pseudogout attack shows that injections of anakinra (interleukin-1 receptor antagonist) were highly effective and safe in nearly three-quarters of patients.  

Through a medical records search they found 100 patients and 115 episodes between 2014-2017 who were treated with anakinra for crystal arthritis.